Olá LATAM

Brazilian Health Ministry Decided to Use Unspent R$17 billion ($3.4 billion) Which was Not utilized During COVID-19 Period Approximately...

ANVISA Drug approvals | Brazil drug approvals | January 2024 | iPharmaCenter

January 09, 2024 Recombinant COVID-19 vaccine is approved by ANVISA in Brazil to prevent COVID-19 infection Designed for the immunization...

Brazil Healthcare News, Pharma News | Drug approved in Brazil | iPharmaCenter

Ondexxya is prescribed for patients undergoing treatment with FXa inhibitors such as apixaban or rivaroxaban when there is an urgent need...

Sign me up!